Amido analogs of mitoxantrone: physico-chemical properties, molecular modeling, cellular effects and antineoplastic potential.
To assess the effects of amido substitution in the side-chains of the anticancer drug mitoxantrone (MX) two analogs were synthesized, having hydroxyethylaminoacetyl- and hydroxyethylaminopropionyl- substituents at the nitrogens located at positions 1, 4 of the anthracenedione ring system. The novel derivatives exhibit DNA-affinity and redox properties similar to the parent drug. However, unlike MX, they are not able to stimulate DNA cleavage, as shown by alkaline elution experiments. Molecular modeling studies using ab initio quantum mechanical methods show that, while the stereochemistry of the drug molecule is not appreciably affected when an amide group replaces the aromatic amino function, the reverse is true for the electrostatic properties. Indeed, overlapping of electron density of MX with its analogs is very poor. Moreover, a reversal in the direction of MX dipole moment occurs in the amido congeners. This may explain the lack of recognition of the cleavable topoisomerase II-DNA complex and loss of cleavage stimulation. However, the new derivatives exhibit pharmacological activity comparable to that found for MX, as they are remarkably cytotoxic and are active in vivo against P388 murine leukemia. Hence, amido substitution may lead to a different mechanism of cytotoxicity, not related to classical protein or free radical-mediated DNA damage, which points to a novel type of antineoplastic pharmacophore.
Zagotto
G
G
Department of Pharmaceutical Sciences, University of Padova, Italy.
Moro
S
S
Uriarte
E
E
Ferrazzi
E
E
Palù
G
G
Palumbo
M
M
D000818:Animals; D000970:Antineoplastic Agents / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology*; D055598:Chemical Phenomena; D002627:Chemistry, Physical; D004247:DNA / Q000187:drug effects / Q000378:metabolism; D004249:DNA Damage; D004354:Drug Screening Assays, Antitumor; D004563:Electrochemistry; D006367:HeLa Cells; D006801:Humans; D007941:Leukemia P388 / Q000188:drug therapy; D051379:Mice; D008942:Mitoxantrone / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology; D010084:Oxidation-Reduction
D000970:Antineoplastic Agents; D004247:DNA; D008942:Mitoxantrone